Moving beyond a heat-labile enterotoxin-based vaccine against enterotoxigenic Escherichia coli

The Lancet Infectious Diseases

Volumn 14, Issue 3, 2014, Pages 174-175

  Riddle, Mark S ^a   Savarino, Stephen J ^a  

^a NAVAL MEDICAL RESEARCH CENTER   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

BACTERIAL TOXINS; DIARRHEA; ENTEROTOXINS; ESCHERICHIA COLI; ESCHERICHIA COLI PROTEINS; ESCHERICHIA COLI VACCINES; FEMALE; HUMANS; MALE; TRAVEL;

BACTERIAL ANTIGEN; CHOLERA TOXIN B SUBUNIT; ENTEROTOXIGENIC ESCHERICHIA COLI VACCINE; ESCHERICHIA COLI ENTEROTOXIN; ESCHERICHIA COLI VACCINE; PLACEBO; UNCLASSIFIED DRUG;

BACTERIAL STRAIN; DIARRHEA; DRUG EFFICACY; ENTEROTOXIGENIC ESCHERICHIA COLI; EUROPE; HUMAN; IMMUNE RESPONSE; IMMUNIZATION; NOTE; PHASE 2 CLINICAL TRIAL (TOPIC); PHASE 3 CLINICAL TRIAL (TOPIC); SOUTH AND CENTRAL AMERICA; THERMOSTABILITY; TRANSDERMAL PATCH;

EID: 84894370523     PISSN: 14733099     EISSN: 14744457     Source Type: Journal    
DOI: 10.1016/S1473-3099(13)70355-4     Document Type: Note

References (12)

1. Behrens RH, Cramer JP, Jelinek T, et al. Efficacy and safety of a patch vaccine containing heat-labile toxin from Escherichia coli against travellers' diarrhoea: a phase 3, randomised, double-blind, placebo-controlled field trial in travellers from Europe to Mexico and Guatemala. Lancet Infect Dis 2013, published online Nov 29. http://dx.doi.org/10.1016/S1473-3099(13)70355-4.
2. The case for investment in enterotoxigenic Escherichia coli vaccines. PATH, BIO Ventures for Global Health PATH, BIO Ventures for Global HealthBIO Ventures for Global Health, (accessed Nov 6, 2013). http://www.path.org/publications/files/VAC-etec-investment-rpt.pdf.
3. Clemens JD, Sack DA, Harris JR, et al. Cross-protection by B subunit-whole cell cholera vaccine against diarrhea associated with heat-labile toxin-producing enterotoxigenic Escherichia coli: results of a large-scale field trial. J Infect Dis 1988, 158:372-377.
4. Peltola H, Siitonen A, Kyrönseppä H, et al. Prevention of travellers' diarrhoea by oral B-subunit/whole-cell cholera vaccine. Lancet 1991, 338:1285-1289.
5. Isidean SD, Riddle MS, Savarino SJ, Porter CK A systematic review of ETEC epidemiology focusing on colonization factor and toxin expression. Vaccine 2011, 29:6167-6178.
6. McKenzie R, Bourgeois AL, Frech SA, et al. Transcutaneous immunization with the heat-labile toxin (LT) of enterotoxigenic Escherichia coli (ETEC): protective efficacy in a double-blind, placebo-controlled challenge study. Vaccine 2007, 25:3684-3691.
7. Frech SA, Dupont HL, Bourgeois AL, et al. Use of a patch containing heat-labile toxin from Escherichia coli against travellers' diarrhoea: a phase II, randomised, double-blind, placebo-controlled field trial. Lancet 2008, 371:2019-2025.
8. Glenn GM, Francis DH, Danielsen EM Toxin-mediated effects on the innate mucosal defenses: implications for enteric vaccines. Infect Immun 2009, 77:5206-5215.
9. Steffen R, Cramer JP, Burchard G, et al. Efficacy of a travelers' diarrhea vaccine system in travelers to India. J Travel Med 2013, 20:374-379.
10. Fleckenstein JM, Munson GM, Rasko D Enterotoxigenic Escherichia coli: orchestrated host engagement. Gut Microbes 2013, 4:392-396.
11. Connor BA, Riddle MS Post-infectious sequelae of travelers' diarrhea. J Travel Med 2013, 20:303-312.
12. Frech S. Use of a patch containing heat-labile toxin from Escherichia coli against travellers' diarrhoea: a phase II, randomised, double-blind, placebo-controlled field trial. 42nd US-Japan Conference on Cholera; Austin, TX, USA; Dec 4-7, 2007.